BIOLASE to Present at the Singular Research Best of the Uncovered 12th Annual Conference 2017

IRVINE, Calif.--()--BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it is scheduled to present at the Singular Research Best of the Uncovered 12th Annual Conference 2017 on Monday, December 4, 2017, at 3:00 PM Pacific Time. BIOLASE President and Chief Executive Officer Harold C. Flynn, Jr. will be giving the presentation and meeting with investors.

The conference is being held at the Hotel Angeleno, 170 North Church Lane, Los Angeles, CA 90049. A live webcast and 90-day replay of the presentation will be available at

About BIOLASE, Inc.

BIOLASE, Inc. is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine and also markets, sells, and distributes dental imaging equipment, including three-dimensional CAD/CAM intra-oral scanners and digital dentistry software. BIOLASE’s products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE’s proprietary laser products incorporate approximately 220 patented and 90 patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. BIOLASE’s innovative products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE’s principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold over 35,500 laser systems to date in over 90 countries around the world. Laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer markets.

For updates and information on Waterlase® iPlus™, Waterlase Express™, and laser dentistry, find BIOLASE online at, Facebook at, Twitter at, LinkedIn at, Instagram at, and YouTube at

BIOLASE® and Waterlase® are registered trademarks of BIOLASE, Inc.

About Singular Research

Singular Research aims to be the most trusted supplier of independent, trusted, single-source research on small-to-micro cap companies to the small-to-medium sized Hedge Fund manager. We will provide quarterly updates for 40 to 70 companies and make recommendations. We find under or overvalued securities, and our goal is to provide initiation reports and quarterly updates for the companies we cover. In most cases, our analysts research companies that are not covered by other firms. We provide honest advice, and our independent analysts have no financial interest in the stocks we cover. Analysts are compensated based on the accuracy of their research calls, not through trading commissions or potential deal flow.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Statements made during BIOLASE’s presentation and its investor meetings at the Singular Research Best of the Uncovered 2017 investor conference in Los Angeles, CA (the “Meetings”), and in its representative’s answers to questions during the Meetings that refer to BIOLASE’s estimated or anticipated future results or other non-historical facts are forward-looking statements, as are any statements its representatives make during the Meetings concerning BIOLASE's strategic initiatives, anticipated financial performance and product launches. Attendees at the Meetings are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations and speak only as of the dates of BIOLASE's participation in the Meetings. Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors affecting BIOLASE’s business including, among others, adverse changes in general economic and market conditions, competitive factors, uncertainty of customer acceptance of new product offerings, risks associated with managing the growth of the business, and those other risks and uncertainties that are described, from time-to-time, in the “Risk Factors” section of BIOLASE's annual and quarterly reports filed with the Securities and Exchange Commission. BIOLASE does not undertake any responsibility to revise or update any forward-looking statements made during its participation in the Conference.


Rene Caron (Investors)
Steve Carr (Investors)
312-726 -3600
Len Hall (Media)

Recent Stories

RSS feed for BIOLASE, Inc.